<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> ....
FERMENTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fermenta Biotech has filed its annual disclosure under SEBI's Large Corporate (LC) framework for FY 2024-25, confirming that it does NOT qualify as a 'Large Corporate' as of March 31, 2025. The company's outstanding borrowings stood at Rs. 28.16 crores, which is below the threshold that would trigger Large Corporate status and the associated mandatory bond issuance requirements. The company holds a credit rating of CARE BBB- with a Stable outlook from CARE Ratings Limited. All incremental borrowing and shortfall-related fields in the disclosure form are marked 'Not Applicable' since the company is outside the LC framework. The filing is signed by the Company Secretary and CFO on April 29, 2025.
This is a routine regulatory compliance filing with no direct impact on shareholders or stock price. The confirmation of non-LC status means Fermenta Biotech has no mandatory debt securities borrowing obligations under SEBI's framework, giving it more flexibility in choosing how to fund operations. The BBB- rating indicates moderate credit quality, which is worth monitoring for any changes.